News

Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently…

Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending…

Barriers including physical difficulties and social stigma may affect how people with Parkinson’s disease use assistive devices meant to help facilitate movement and prevent falls, a study found. Parkinson’s patients said physicians prescribing assistive devices helped them overcome stigma or negative associations. Other possible interventions, including education initiatives and…

A gene therapy tool dubbed AAV-DB-3, being developed by Latus Bio to deliver therapeutic genetic material into cells, is able to reach deep structures in the brain — among them ones that become damaged in neurodegenerative disorders such as Parkinson’s disease — a study in mice, monkeys, and lab-grown…

REM sleep behavior disorder (RBD) can mean restless nights for people with Parkinson’s disease and their partners, and add to symptoms, such as cognitive impairment and problems with blood pressure or digestion, that make daily life more difficult for both, a study shows. To ease any tension, couples often…

Unixell Biotechnology has dosed its first Parkinson’s disease patient in a clinical study of its stem cell therapy candidate, UX-DA001. According to a press release from Unixell, a surgeon at Ruijin Hospital in Shanghai successfully injected the experimental medication directly into a patient’s brain. UX-DA001 is derived from…

Risvodetinib, an experimental oral small molecule Abli Therapeutics is developing for people with untreated Parkinson’s disease, may be one step closer to Phase 3 clinical testing, following a meeting with U.S. regulators. The end-of-Phase 2 meeting’s main goal with the U.S. Food and Drug Administration (FDA) was to…

Walk in New York, a new clinic from Wandercraft, will allow people with Parkinson’s disease to access robotic-assisted training intended to help in the rehabilitation of patients’ walking ability. “Our mission has always been to restore everyday mobility, building hand in hand with the community of people…

Treatment with Askbio‘s gene therapy candidate AB-1005 is safe and appears to ease motor symptoms in people with either a recent or a long-standing diagnosis of Parkinson’s disease. That’s according to the full results of a small Phase 1 clinical trial conducted by the gene therapy’s developer at three…

The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop a brain-selective therapy for Parkinson’s disease using the company’s Brainonly platform. As part of the project, Montara will design and develop an LRRK2 inhibitor drug candidate that can reach…